Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis

• DOI: 10.3390/diagnostics14010016
• Publication Date: 2023-12-21T08:36:17Z
• Authors: Razan Al Namat; Letiția Doina Duceac; Liliana Chelaru; Marius Gabriel Da...; Cristian Guțu; Constantin Marcu; Maria Valentina Popa; Florina Popa; Elena Roxana Bogd...; Elena Țarcă
• Keywords: Prediabetes

Introduction: Increasingly, SGLT2 inhibitors save patients with heart failure and comorbidities such as type-2 diabetes mellitus (T2DM) chronic kidney disease (CKD); the inhibition of sodium-glucose cotransporter 2 (SGLT2) was first studied in a solution to lower glucose levels by preventing reabsorption facilitating its elimination; process, researchers took notice how also seemed have beneficial cardiovascular effects both disease. Aim: Our single-center prospective study assesses outcomes post-coronary artery bypass grafting (CABG) rehabilitation SLGT2 CABG with/without T2DM CKD. Materials Methods: One hundred twenty consecutive undergoing were included analysis. Patients divided into four subgroups: (T2DM + CKD), without (T2DM−CKD), prediabetes (PreD+CKD), (PreD−CKD). Echocardiographic laboratory investigations post-surgery (phase I) 6 months later II) markers for cardiac ischemia, glycemic status, renal function, metabolic equivalents investigated. Results: participated, mostly men, overweight/obese, hypertensive, smokers; 65 had (18 55 prediabetic (17 CKD). The mean ejection fraction increased 8.43% overall but significantly more group compared (10.14% vs. 6.98%, p < 0.05). Overall, heart-type fatty-acid-binding protein (H-FABP) returned normal levels, dropping from 68.40 ng/mL 4.82 (p = 0.000), troponin data nuanced relative an overall, strongly significant decrease 44,458 ng/L 0.000). Troponin CKD dropped more, presence (by 82,500 ng/L, 0.000) 73,294 0.047). As expected, glycated hemoglobin (HbA1c) improved those (from 6.54% 5.55%, 0.000); on other hand, HbA1c changed 7.06% 6.06% T2DM, or absence did not seem make any difference: T2DM+CKD 7.01–6.08% T2DM−CKD 7.08–6.04% PreD+CKD 5.66–4.98% 0.014), PreD−CKD 6.03–4.94% 0.00). Compared gain 11.51, GFRs 18.93 (68.15–87.07%, established 14.89 (64.75–79.64%, group. Conclusions: Regarding patients’ statuses, results our analysis revealed ischemic risk (H-FABP hs-cTnI levels) improvements fraction, function post-CABG CKD, inhibitor dapagliflozin treatment while rehabilitation.